Emanuel
2021-12-01
Oh no! Any comments ?
Longeveron stock tumbled 20% in premarket trading<blockquote>Longeveron股价在盘前交易中暴跌20%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603985630,"tweetId":"603985630","gmtCreate":1638352200740,"gmtModify":1638352200823,"author":{"id":3575613739783302,"idStr":"3575613739783302","authorId":3575613739783302,"authorIdStr":"3575613739783302","name":"Emanuel","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Oh no! Any comments ? </p></body></html>","htmlText":"<html><head></head><body><p>Oh no! Any comments ? </p></body></html>","text":"Oh no! Any comments ?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603985630","repostId":1121529054,"repostType":2,"repost":{"id":"1121529054","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638351626,"share":"https://www.laohu8.com/m/news/1121529054?lang=zh_CN&edition=full","pubTime":"2021-12-01 17:40","market":"us","language":"en","title":"Longeveron stock tumbled 20% in premarket trading<blockquote>Longeveron股价在盘前交易中暴跌20%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1121529054","media":"Tiger Newspress","summary":"Longeveron stock tumbled 20% in premarket trading after it announced pricing of a $20.5 million priv","content":"<p>Longeveron stock tumbled 20% in premarket trading after it announced pricing of a $20.5 million private placement.</p><p><blockquote>在宣布2050万美元私募定价后，Longeveron股价在盘前交易中暴跌20%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0985d049774f6ccfb31d70504c9d0506\" tg-width=\"851\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Longeveron Inc. today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement.</p><p><blockquote>Longeveron Inc.今天宣布，它与某些机构投资者签订了证券购买协议，以私募方式购买价值约2050万美元的普通股和认股权证。</blockquote></p><p> Under the terms of the securities purchase agreement, the Company has agreed to sell approximately 1.17 million shares of its common stock and warrants to purchase 1.17 million shares of common stock. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $17.50 per share. The warrants will expire five years from the date of issuance. The purchase price for one share of common stock and one corresponding warrant will be $17.50. The gross proceeds to the Company from the private placement are estimated to be approximately $20.5 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 3, 2021, subject to the satisfaction of customary closing conditions.</p><p><blockquote>根据证券购买协议的条款，公司已同意出售约117万股普通股和购买117万股普通股的认股权证。认股权证将于发行之日立即行使，行使价为每股17.50美元。认股权证将自发行之日起五年后到期。一股普通股和一份相应认股权证的购买价格为17.50美元。在扣除配售代理费用和其他预计发行费用之前，公司从私募中获得的总收益估计约为2050万美元。此次发行预计将于2021年12月3日左右结束，具体取决于惯例成交条件的满足。</blockquote></p><p> Longeveron intends to use the net proceeds from the private placement to support the ongoing clinical development of Lomecel-B, the Company’s lead investigational product, which is currently being evaluated as a potential therapeutic for Hypoplastic Left Heart Syndrome, Aging Frailty Alzheimer’s Disease and other diseases. In addition, the Company plans to use the proceeds to fund additional research and development, product development, and for general and administrative purposes.</p><p><blockquote>Longeveron打算将此次私募的净收益用于支持该公司主要研究产品Lomecel-B的持续临床开发，该产品目前正在被评估为左心发育不全综合征、老年性虚弱阿尔茨海默病和其他疾病的潜在治疗药物。此外，公司计划将所得款项用于资助额外的研发、产品开发以及一般和行政用途。</blockquote></p><p> EF Hutton, division of Benchmark Investments, LLC, is acting as exclusive placement agent for the offering.</p><p><blockquote>Benchmark Investments，LLC的部门EF Hutton是此次发行的独家配售代理。</blockquote></p><p> <b>About Longeveron Inc.</b></p><p><blockquote><b>关于Longeveron公司。</b></blockquote></p><p> Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.</p><p><blockquote>Longeveron是一家临床阶段的生物技术公司，开发针对特定衰老相关和危及生命的疾病的细胞疗法。该公司的主要研究产品是LOMECEL-B™基于细胞的治疗产品（“Lomecel-B”），其源自来自年轻健康成人供体骨髓的培养扩增的药用信号细胞（MSC）。Longeveron认为，通过使用促进组织修复、器官维护和免疫系统功能的相同细胞，它可以为一些与衰老过程和其他医学疾病相关的最困难的疾病开发安全有效的疗法。Longeveron目前正在赞助以下适应症的1期和2期临床试验：衰老虚弱、阿尔茨海默病、代谢综合征、急性呼吸窘迫综合征（ARDS）和左心发育不全综合征（HLHS）。该公司的使命是将Lomecel-B和其他基于细胞的候选产品推进到关键的3期试验，目标是获得监管机构的批准、随后的商业化和医疗保健界的广泛使用。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron stock tumbled 20% in premarket trading<blockquote>Longeveron股价在盘前交易中暴跌20%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron stock tumbled 20% in premarket trading<blockquote>Longeveron股价在盘前交易中暴跌20%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-01 17:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Longeveron stock tumbled 20% in premarket trading after it announced pricing of a $20.5 million private placement.</p><p><blockquote>在宣布2050万美元私募定价后，Longeveron股价在盘前交易中暴跌20%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0985d049774f6ccfb31d70504c9d0506\" tg-width=\"851\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Longeveron Inc. today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement.</p><p><blockquote>Longeveron Inc.今天宣布，它与某些机构投资者签订了证券购买协议，以私募方式购买价值约2050万美元的普通股和认股权证。</blockquote></p><p> Under the terms of the securities purchase agreement, the Company has agreed to sell approximately 1.17 million shares of its common stock and warrants to purchase 1.17 million shares of common stock. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $17.50 per share. The warrants will expire five years from the date of issuance. The purchase price for one share of common stock and one corresponding warrant will be $17.50. The gross proceeds to the Company from the private placement are estimated to be approximately $20.5 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 3, 2021, subject to the satisfaction of customary closing conditions.</p><p><blockquote>根据证券购买协议的条款，公司已同意出售约117万股普通股和购买117万股普通股的认股权证。认股权证将于发行之日立即行使，行使价为每股17.50美元。认股权证将自发行之日起五年后到期。一股普通股和一份相应认股权证的购买价格为17.50美元。在扣除配售代理费用和其他预计发行费用之前，公司从私募中获得的总收益估计约为2050万美元。此次发行预计将于2021年12月3日左右结束，具体取决于惯例成交条件的满足。</blockquote></p><p> Longeveron intends to use the net proceeds from the private placement to support the ongoing clinical development of Lomecel-B, the Company’s lead investigational product, which is currently being evaluated as a potential therapeutic for Hypoplastic Left Heart Syndrome, Aging Frailty Alzheimer’s Disease and other diseases. In addition, the Company plans to use the proceeds to fund additional research and development, product development, and for general and administrative purposes.</p><p><blockquote>Longeveron打算将此次私募的净收益用于支持该公司主要研究产品Lomecel-B的持续临床开发，该产品目前正在被评估为左心发育不全综合征、老年性虚弱阿尔茨海默病和其他疾病的潜在治疗药物。此外，公司计划将所得款项用于资助额外的研发、产品开发以及一般和行政用途。</blockquote></p><p> EF Hutton, division of Benchmark Investments, LLC, is acting as exclusive placement agent for the offering.</p><p><blockquote>Benchmark Investments，LLC的部门EF Hutton是此次发行的独家配售代理。</blockquote></p><p> <b>About Longeveron Inc.</b></p><p><blockquote><b>关于Longeveron公司。</b></blockquote></p><p> Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.</p><p><blockquote>Longeveron是一家临床阶段的生物技术公司，开发针对特定衰老相关和危及生命的疾病的细胞疗法。该公司的主要研究产品是LOMECEL-B™基于细胞的治疗产品（“Lomecel-B”），其源自来自年轻健康成人供体骨髓的培养扩增的药用信号细胞（MSC）。Longeveron认为，通过使用促进组织修复、器官维护和免疫系统功能的相同细胞，它可以为一些与衰老过程和其他医学疾病相关的最困难的疾病开发安全有效的疗法。Longeveron目前正在赞助以下适应症的1期和2期临床试验：衰老虚弱、阿尔茨海默病、代谢综合征、急性呼吸窘迫综合征（ARDS）和左心发育不全综合征（HLHS）。该公司的使命是将Lomecel-B和其他基于细胞的候选产品推进到关键的3期试验，目标是获得监管机构的批准、随后的商业化和医疗保健界的广泛使用。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121529054","content_text":"Longeveron stock tumbled 20% in premarket trading after it announced pricing of a $20.5 million private placement.\n\nLongeveron Inc. today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement.\nUnder the terms of the securities purchase agreement, the Company has agreed to sell approximately 1.17 million shares of its common stock and warrants to purchase 1.17 million shares of common stock. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $17.50 per share. The warrants will expire five years from the date of issuance. The purchase price for one share of common stock and one corresponding warrant will be $17.50. The gross proceeds to the Company from the private placement are estimated to be approximately $20.5 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 3, 2021, subject to the satisfaction of customary closing conditions.\nLongeveron intends to use the net proceeds from the private placement to support the ongoing clinical development of Lomecel-B, the Company’s lead investigational product, which is currently being evaluated as a potential therapeutic for Hypoplastic Left Heart Syndrome, Aging Frailty Alzheimer’s Disease and other diseases. In addition, the Company plans to use the proceeds to fund additional research and development, product development, and for general and administrative purposes.\nEF Hutton, division of Benchmark Investments, LLC, is acting as exclusive placement agent for the offering.\nAbout Longeveron Inc.\nLongeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.","news_type":1,"symbols_score_info":{"LGVN":0.9}},"isVote":1,"tweetType":1,"viewCount":440,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603985630"}
精彩评论